Literature DB >> 23410821

Central serous chorioretinopathy: update on pathophysiology and treatment.

Benjamin Nicholson1, Jason Noble, Farzin Forooghian, Catherine Meyerle.   

Abstract

Recent technological advances--new pathophysiological insights, new imaging techniques for diagnosis and management, and new treatments--have led to an improved understanding of central serous chorioretinopathy (CSC). The primary role of the choroid has become more widely accepted with widespread use of indocyanine green angiography. Optical coherence tomography (OCT), and particularly enhanced depth imaging OCT, demonstrate a thickened and engorged choroid. Adaptive optics, fundus autofluorescence, multifocal electroretinography, microperimetry, and contrast sensitivity testing reveal that patients with even a mild course suffer previously undetected anatomic and functional loss. Although focal laser and photodynamic therapy are the current standard of care for persistent subretinal fluid in CSC, they are not appropriate in all cases, and the optimal timing of intervention remains unclear. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23410821      PMCID: PMC3574296          DOI: 10.1016/j.survophthal.2012.07.004

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  235 in total

1.  Familial central serous choroidopathy.

Authors:  E Lin; P G Arrigg; R Y Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2000-11       Impact factor: 3.117

2.  Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.

Authors:  Kyoko Fujita; Mitsuko Yuzawa; Ryusaburou Mori
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

3.  Correlations among various functional and morphological tests in resolved central serous chorioretinopathy.

Authors:  Seong-Woo Kim; Jaeryung Oh; Kuhl Huh
Journal:  Br J Ophthalmol       Date:  2011-05-26       Impact factor: 4.638

4.  Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy.

Authors:  Keiichi Mitarai; Fumi Gomi; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-05       Impact factor: 3.117

5.  Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.

Authors:  T Y Y Lai; W-M Chan; H Li; R Y K Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

6.  Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy.

Authors:  Lazaros Konstantinidis; Irmela Mantel; Leonidas Zografos; Aude Ambresin
Journal:  Eur J Ophthalmol       Date:  2010 Sep-Oct       Impact factor: 2.597

7.  Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids.

Authors:  R Haimovici; E S Gragoudas; J S Duker; R N Sjaarda; D Eliott
Journal:  Ophthalmology       Date:  1997-10       Impact factor: 12.079

Review 8.  Type-A behavior and central serous chorioretinopathy.

Authors:  L A Yannuzzi
Journal:  Retina       Date:  1987       Impact factor: 4.256

9.  The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy.

Authors:  Mohammad Bagher Rahbani-Nobar; Alireza Javadzadeh; Leila Ghojazadeh; Mandana Rafeey; Amir Ghorbanihaghjo
Journal:  Mol Vis       Date:  2011-01-11       Impact factor: 2.367

10.  Fundus Autofluorescence and Spectral Domain OCT in Central Serous Chorioretinopathy.

Authors:  Luiz Roisman; Daniel Lavinsky; Fernanda Magalhaes; Fabio Bom Aggio; Nilva Moraes; Jose A Cardillo; Michel E Farah
Journal:  J Ophthalmol       Date:  2011-08-08       Impact factor: 1.909

View more
  159 in total

1.  Evaluation of Choroidal Thickness and Volume during the Third Trimester of Pregnancy using Enhanced Depth Imaging Optical Coherence Tomography: A Pilot Study.

Authors:  Renata T Rothwell; Dália M Meira; Marisa A Oliveira; Lígia F Ribeiro; Sofia L Fonseca
Journal:  J Clin Diagn Res       Date:  2015-08-01

2.  Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy.

Authors:  Seoung Hyun An; Yoon Hyung Kwon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-09       Impact factor: 3.117

3.  Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.

Authors:  Serra Arf; Mumin Hocaoglu; Isil Sayman Muslubas; Murat Karacorlu
Journal:  Int Ophthalmol       Date:  2016-07-08       Impact factor: 2.031

4.  Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.

Authors:  Wookyung Park; Mirinae Kim; Rae Young Kim; Young-Hoon Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-31       Impact factor: 3.117

5.  Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up.

Authors:  A Arsan; H S Kanar; A Sonmez
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

6.  Finasteride is effective for the treatment of central serous chorioretinopathy.

Authors:  E Moisseiev; A J Holmes; A Moshiri; L S Morse
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

7.  Choroidal binarization analysis: clinical application.

Authors:  Sara Crisostomo; Joana Cardigos; Diogo Hipólito Fernandes; Maria Elisa Luís; Ricardo Figueiredo; Nuno Moura-Coelho; João Paulo Cunha; Luís Abegão Pinto; Joana Ferreira
Journal:  Int Ophthalmol       Date:  2019-05-28       Impact factor: 2.031

8.  Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients.

Authors:  Young Gun Park; Seungbum Kang; Minhee Kim; Nari Yoo; Young Jung Roh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-18       Impact factor: 3.117

9.  Corticosteroid-associated atypical central serous chorioretinopathy in a patient with multiple sclerosis.

Authors:  Mahmut Kaya; Derya Kaya; Egemen Idiman
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

10.  Development of an efficient algorithm for the detection of macular edema from optical coherence tomography images.

Authors:  K M Jemshi; Varun P Gopi; Swamidoss Issac Niwas
Journal:  Int J Comput Assist Radiol Surg       Date:  2018-05-29       Impact factor: 2.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.